{
    "id": 29312,
    "fullName": "APP - NRG1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "APP-NRG1 results from the fusion of APP and NRG1 (PMID: 29802158). APP-NRG1 fusions that result in the insertion of the EGF1-like domain of Nrg1 into App have been identified in pancreatic ductal adenocarcinoma (PMID: 29802158, PMID: 31068372), but have not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 13943,
                    "pubMedId": 29802158,
                    "title": "NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29802158"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 16389,
                    "pubMedId": 31068372,
                    "title": "NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31068372"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 351,
        "geneSymbol": "APP",
        "terms": [
            "APP",
            "AAA",
            "ABETA",
            "ABPP",
            "AD1",
            "APPI",
            "CTFgamma",
            "CVAP",
            "PN-II",
            "PN2",
            "preA4"
        ]
    },
    "variant": "APP - NRG1",
    "createDate": "02/05/2019",
    "updateDate": "11/14/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 3084,
                "geneSymbol": "NRG1",
                "terms": [
                    "NRG1",
                    "ARIA",
                    "GGF",
                    "GGF2",
                    "HGL",
                    "HRG",
                    "HRG1",
                    "HRGA",
                    "MST131",
                    "MSTP131",
                    "NDF",
                    "NRG1-IT2",
                    "SMDF"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15909,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case\u00a0study,\u00a0a patient\u00a0with\u00a0KRAS wild-type pancreatic ductal adenocarcinoma\u00a0harboring\u00a0an APP-NRG1 fusion had stable disease and improved liver function after 12 weeks of\u00a0combined\u00a0Tarceva (erlotinib),\u00a0Herceptin (trastuzumab), Abraxane (nab-paclitaxel), Adrucil (5-fluorouracil), and Wellcovorin (leucovorin) therapy (PMID: 29802158).",
            "molecularProfile": {
                "id": 31310,
                "profileName": "APP - NRG1 KRAS wild-type"
            },
            "therapy": {
                "id": 7804,
                "therapyName": "Erlotinib + Fluorouracil + Leucovorin + Nab-paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13943,
                    "pubMedId": 29802158,
                    "title": "NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29802158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18705,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in significant radiologic response and resolution of metastasis 4 weeks after initiation of therapy in a patient with KRAS wild-type pancreatic ductal adenocarcinoma harboring an ATP1B1-NRG1 fusion, and he continued on treatment after 5 months (PMID: 31068372).",
            "molecularProfile": {
                "id": 31310,
                "profileName": "APP - NRG1 KRAS wild-type"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16389,
                    "pubMedId": 31068372,
                    "title": "NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31068372"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31310,
            "profileName": "APP - NRG1 KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33502,
            "profileName": "APP - NRG1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}